Italy to Receive 40,000 Merck Antiviral Drug Doses Next Week: Official

Italy to Receive 40,000 Merck Antiviral Drug Doses Next Week: Official
An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co. Inc. and Ridgeback Biotherapeutics LP. (Merck & Co. Inc./Handout via Reuters)
Reuters
1/10/2022
Updated:
1/10/2022

MILAN—Italy will receive around 40,000 doses of Merck & Co.’s COVID-19 antiviral drug next week, which will add to nearly 12,000 already distributed to hospitals, the special COVID-19 commissioner said on Sunday.

“They are intended for clinical cases that risk a serious outcome of the disease,” Commissioner Francesco Figliuolo told a television program on Italy’s RAI 3 channel.

Italy will also get 200,000 courses of Pfizer’s COVID-19 drug in February, Figliuolo said, adding that Rome had an option to buy additional 400,000 doses of Pfizer’s Paxlovid.

The office of the special commissioner for the COVID emergency said in November it had received a mandate from the health ministry to buy 50,000 courses of Merck’s pill and another 50,000 of Pfizer’s one.